Optimi Health Provides Corporate Update
VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, announces that it intends to close the final tranche of its non-brokered private placement imminently (the “Offering”).
Related news for (OPTHF)
- Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
- Optimi Health Obtains U.S. FDA Drug Establishment Registration
- Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
- Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement